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Background. Cryptococcal meningitis is a major cause of death among people with human immunodeficiency virus (PWH).
Cryptococcal antigen (CrAg) testing of asymptomatic patients is an important public health measure to reduce mortality in highincidence areas. However, limited data exist on CrAg prevalence in Central America.
Methods. We conducted a prospective cohort study at the 2 largest human immunodeficiency virus (HIV) clinics and hospitals
in Honduras. Cryptococcal antigen in serum and cerebrospinal fluid was performed in individuals with HIV who had CD4 ≤100
cells/mm3 between 2017 and 2018. After CrAg testing, individuals were observed for 12 months to assess mortality using adjusted
Cox proportional hazard models.
Results. A total of 220 PWH were tested for CrAg, 12.7% (n = 28) of which tested positive. Cryptococcal antigen prevalence was
higher among hospitalized individuals in 40% (n = 10 of 25) of the cases. The proportion (35.8%) of individuals taking antiretroviral
therapy was significantly (P < .01) lower among those who tested positive for CrAg. Overall mortality among the cohort was 11.4%
(n = 25 of 220) by 12 months. Cryptococcal antigen-positive cases were at a significantly higher risk of death (adjusted hazard ratio,
2.69; 95% confidence interval, 1.07–6.84) compared with CrAg-negative participants.
Conclusions. Cryptococcal antigen prevalence in Honduras was high among PWH. Moreover, individuals who tested positive
for CrAg testing were at a higher risk of death. Systemic CrAg of PWH with a CD4 ≤100 cells/mm3 should be routinely performed
in Central America.
Keywords. cryptococcal antigen; Honduras; Latin America; PWH.
Cryptococcal meningitis (CM) remains one of the leading
causes of death among people with human immunodeficiency
virus (PWH) worldwide, with as many as 15% of the deaths
in PWH being attributed to CM [1]. With the development
of the cryptococcal antigen (CrAg) lateral-flow assay, an inexpensive point-of-care test, diagnoses are now accessible in
low-income countries [2–4], allowing clinicians to screen for
asymptomatic antigenemia. This approach has been proven to
be cost-effective [5] and to decrease the number of deaths attributed to CM [6].
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Despite the availability of screening and diagnostic tools for
cryptococcal antigenemia in low-income nations, little is known
about cryptococcal antigenemia and its burden in Central
American countries. Although recent evidence suggests high
burden of CM in Latin America, Central America was not represented, because no studies exist from this region [1]. Efforts
to address this gap have been mostly undertaken in South
American countries [7–9] rather than in Central America or the
Caribbean, where the burden of human immunodeficiency virus
(HIV) is high [10] and the epidemic is worsening [11]. Honduras
has recently reported high mortality rates associated with CM in
individuals with HIV [12]. The burden of this diseases remains
unknown in Honduras or any other part of Central America.
The World Health Organization (WHO) recommends screening
for CrAg in PWH with a CD4 ≤100 cells/mm3 [13].
To address a public health concern associated with cryptococcosis as an opportunistic infection in PWH in Central
America, and to address the knowledge gap surrounding cryptococcal disease burden, we conducted a prospective cohort
study to determine CrAg prevalence and outcomes associated
at the 2 largest clinics serving PWH in Honduras.
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Prevalence of Cryptococcal Antigen and Outcomes
in People With Human Immunodeficiency Virus in
Honduras: A Cohort Study

METHODS
Participants

Enrollment and Procedures

Using the HIV outpatient clinics records and laboratory reports,
we were able to identify eligible individuals for CrAg screening.
At enrollment, clinical and demographic data were collected
using URC-CDC Cryptococcosis and Histoplasmosis [14] case
surveillance forms. In addition, a single whole blood sample was
collected on each participant to test for CrAg using the Lateral
Flow Assay (IMMY, Norman, OK) in serum. Participants with
a positive serum CrAg were contacted 24 hours after the test
was performed in serum and assessed for CM with a lumbar
puncture (LP) to rule out CM. Individuals who presented with
clinical findings that suggested central nervous system (CNS)
compromise such as seizures, headache, and stiffness of neck
had a cerebrospinal fluid (CSF) CrAg performed only.
Due to the lack of availability of flucytosine in Honduras,
participants with positive CSF CrAg received therapy with
0.5 mg/kg amphotericin B deoxycholate and 800 mg of intravenous fluconazole daily for 14 days followed by 400 mg of
oral fluconazole for 8 weeks and 200 mg afterwards. When
amphotericin B deoxycholate was not available, 1200 mg of
fluconazole was given daily for 14 days. Individuals who tested
positive for CrAg in serum and negative in CSF received ambulatory therapy with 800 mg of oral fluconazole daily for 2 weeks
followed by 200 mg daily for an additional 8 weeks [13].
The follow-up period conducted by the research team was
composed of 4 visits within 12 months, where clinical examination was performed to assess potential symptoms of cryptococcal disease or recurrence for those individuals who tested
positive for CrAg. Participants with a negative serum CrAg
underwent routine follow up by their HIV clinic physicians,
and potential cryptococcal disease after clinical examination
was reported to the research team. Mortality was confirmed
during the 12-month follow-up period using national registries
2 • ofid • Zuniga-Moya et al

Statistical Analysis

For the statistical analysis, the cohort was divided in CrAgpositive and CrAg-negative groups. Descriptive statistics were
performed, and P values were calculated using Fisher’s exact
test, χ 2 test, or Wilcoxon rank-sum test as needed. To gauge risk
of mortality after 12-month follow up, Cox proportional hazard
models were used adjusting for age and antiretroviral therapy
(ART). Data were analyzed using R version 3.6.1 (available at
https://www.R-project.org/) using the package “survival”.
Patient Consent Statement

The institutional review boards at Universidad Catolica de
Honduras and Hospital Escuela Universitario approved the research protocol. Written informed consent was obtained from
PWH 18 years or older and from parents for children <12 years
old; assent was obtained from children ≥12 years old, as per the
guidance of the review boards.
RESULTS
Population Baseline Characteristics

We enrolled 195 individuals in the outpatient clinics (screening)
and 25 at the inpatient infectious diseases’ units in both hospitals (Figure 1). Overall, the median age was 38 years (interquartile range [IQR], 30–46 years), 64.7% (n = 140) were males,
and 93.6% (n = 206) were from urban areas. The median CD4
was 46 cells/mm3 (IQR, 25–72 cells/mm3), and 67% (n = 147)
were receiving ART at the time of antigen testing (Table 1). The
median duration of time since HIV diagnosis was 21 months
(IQR, 1–111 months) among the cohort.
Cryptococcal Antigen Prevalence

Of the 220 enrolled, 12.7% (n = 28) of the individuals had a
positive CrAg in either the CSF or serum. Furthermore, among
participants who attended the outpatient clinics, 9.2% (n = 18)
tested positive for CrAg. Forty percent (n = 10) of the participants who were hospitalized tested positive for CrAg.
Overall, 9.2% (n = 18) of the outpatient participants tested
positive for CrAg in serum. All participants who tested positive
for CrAg in serum at baseline consented to be tested for CrAg
in CSF through LP. Fifty percent (n = 9) of the participants who
tested CrAg positive in serum also tested positive for CrAg in
CSF after LP. Furthermore, of 25 individuals who were only
tested in CSF due to their clinical manifestations compatible
with CNS compromise, 64% (n = 16) tested negative.
Antiretroviral therapy receipt at baseline was significantly
lower among individuals who tested positive for CrAg compared with those who tested negative (P = .03). Furthermore,
the proportion of individuals taking fluconazole for Candida
prophylaxis was significantly lower within those who tested
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Between April 2017 and December 2018, we conducted a prospective cohort study at 2 outpatient HIV clinics in San Pedro
Sula and Tegucigalpa, Honduras as well as at the inpatient
Infectious Disease Units of Hospital “Escuela Universitario”
and “Mario Catarino Rivas” in both cities. Medical records
and laboratory reports were used to identify eligible participants. This study was nested on a URC-Centers for Disease
Control and Prevention (CDC) mycotic infections surveillance
on PWH. We included PWH with a CD4 ≤100 cells/mm3 who
presented to either HIV clinic or the inpatient units during
the study period regardless of age. Participants were excluded
if they had a previous diagnosis of cryptococcosis. All participants who complied with the study criteria and attended either
the ambulatory clinic or hospitals were approached, and all who
consented were included in a sequential manner.

and hospital registries at both HIV clinics to minimize loss to
follow up.

Ambulatory clinics
(n = 195)

Hospitalized
individuals*
(n = 25)

Individuals enrolled
(n = 220)

CrAg negative
(n = 192)

Serum CrAg
(n = 18)

LTFU (n = 5)
Deaths in 1-year (n = 18)

CSF CrAg
(n = 10)
Deaths in 1-year
(n = 6)

CrAg positive in CSF
after LP
(n = 9)

Deaths in 1-year
(n = 1)
Figure 1. Flowchart of enrollment at human immunodeficiency virus clinics and hospitals in Honduras. *, Hospitalized individuals were only tested in cerebrospinal fluid
(CSF). CrAg, cryptococcal antigen; LTFU, lost to follow-up.

Fever (64.5% of cases), weight loss (56.8% of cases), and
headache (50.5% of cases) were the 3 most frequent clinical

features among the cohort. This finding was consistent in
both CrAg-positive and CrAg-negative participants. Of all
the participants, 9.1% (n = 19) had no signs or symptoms at
baseline and thus were considered asymptomatic (Table 2).
Thirty-six percent (n = 9 of 25) of the hospitalized individuals had clinical manifestations of CM that was confirmed
with a CrAg-positive test in CSF. Median age of individuals

Table 1. Baseline Characteristics of Patients Enrolled for Cryptococcal
Antigen Testing in Honduras

Table 2. Baseline Clinical Features of 220 PWH in Honduras by CrAg
Status

positive for CrAg (P = .04) as was the time since diagnosis of
HIV, which was significantly lower (P < .01) among those who
tested positive for CrAg in the cohort (Table 1).
Clinical Features and Outcomes

Baseline Characteristics

Total
CrAg Positive CrAg Negative
n = 220 (%)
n = 28 (%)
n = 192 (%)
Pa

Total n = 220

Age years (median [IQR])

38 [30–45.5]

Clinical Features

36 [28.5–
46.5]

Pa

.86

Weight loss

118 (61.5)

17 (60.7)

.93

.83

Fever

117 (60.9)

25 (89.3)

<.01

Headache

93 (48.4)

18 (64.3)

.11

Cough

78 (40.6)

10 (35.7)

.62

Diarrhea

74 (38.5)

7 (25.0)

.16

Oral lesions

56 (29.2)

9 (32.1)

.74

Nausea

54 (28.1)

17 (60.7)

<.01

Wasting syndrome

46 (23.9)

12 (42.9)

.03

Dyspnea

42 (21.9)

6 (21.4)

.95

Mental status impairment

27 (14.1)

11 (39.3)

<.01

Cranial nerve compromise

18 (9.4)

5 (17.9)

.09

Seizures

10 (5.2)

3 (10.7)

.25

7 (25.9)

<.01

140 (63.7)

17 (60.7)

123 (64.0)

Urban residence

206 (93.6)

25 (89.3)

181 (94.3)

.39

Taking ART

147 (66.8)

10 (35.8)

137 (71.4)

<.01

CD4 count cells/mm3 (median [IQR])

46 [25–72]

40 [23.75–54]

48 [25–72]

.20

Time since HIV diagnosis in 21 [1–111]
months (median [IQR])

1 [1–51]

36 [1–120]

<.01

History of previous mycosis

47 (21.4)

5 (17.9)

42 (21.9)

.80

Fluconazole prophylaxis

98 (44.5)

7 (25.0)

91 (47.4)

.04

Hemoglobin g/dL (median
[IQR])

11.3 [9.5–
12.72]

Hospitalized participants

25 (11.4)

11.0 [8.85– 11.3[9.50–12.7] .52
12.7]
16 (8.3)

<.01

Abbreviations: ART, antiretroviral therapy; CrAg, cryptococcal antigen; HIV, human immunodeficiency virus; IQR, interquartile range.
a 2

CrAg Positive
n = 28 (%)

38 [31–45.3]

Male sex

9 (32.1)

CrAg Negative
n = 192 (%)

χ , Fisher’s exact test, or Wilcoxon rank-sum test as appropriate to compare CrAg-positive
and CrAg-negative groups.

Nape rigidity

6 (3.13)

Abbreviations: CrAg, cryptococcal antigen; PWH, people with human immunodeficiency
virus.
a 2

χ test/Fisher’s exact test as appropriate.
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CrAg positive
(n = 28)

Strata

DISCUSSION

To our knowledge, this the first study to assess CrAg prevalence
and outcomes in Central America, demonstrating a high prevalence of 12.7% among PWH whose CD4 was ≤100 cells/mm3.
Although previous models have estimated that the burden of
cryptococcal disease is high in Latin America [1], these models
were built in absence of any data from Central America. This
study allows for updates for the world estimates of cryptococcosis and informs the need for CrAg screening of PWH with
a CD4 ≤100 cells/mm3 in Central America. Furthermore, this
study describes the risk of death among individuals tested for
CrAg during a 12-month follow-up period in an unexplored
HIV cohort.
The overall prevalence of CrAg among the Honduran cohort
was 12.7%. This finding is particularly high when compared
with other African low-income settings where CrAg prevalence
ranges from 4% to almost 10% [15–17]. Furthermore, when
gauging the characteristics of those participants who tested
positive for CrAg, our findings are comparable to reports elsewhere [15–17] where young males are more likely to test positive for CrAg.
Although little is known about the prevalence of cryptococcal
antigenemia in Central American countries, some reports have
estimated its prevalence in South American countries. Our
findings suggest that cryptococcal antigenemia prevalence is
potentially higher than most of the studies in South America
[8, 9, 18]. However, testing among these cohorts was performed
on individuals with CD4 <200 cell/mm3 [7, 8], and thus this

CrAg negative

CrAg positive

Survival probability

1.00

0.75

0.50

0.25

p = .011

0.00
0

3

Strata

Number at risk

Figure 2.

6

9

12

Time in months

CrAg negative

192

186

179

176

174

CrAg positive

28

25

22

22

21

0

3

6
Time in months

9

12

Kaplan-Meier 12-month survival analysis comparing cryptococcal antigen (CrAg)-positive individuals with CrAg-negative.

4 • ofid • Zuniga-Moya et al

Downloaded from https://academic.oup.com/ofid/article/8/1/ofaa557/5981349 by Washington University in St. Louis user on 27 February 2021

with CM was 40 years (IQR, 33–43), and male sex was predominant with 66.7% (n = 6) of the cases. Furthermore,
median CD4 was 40 cells/mm3 (IQR, 28–58 cells/mm3).
Sixty-six percent (n = 6) of individuals with CM were taking
ART at the time of the diagnosis.
Eleven percent (n = 25) of study participants died during the
12-month follow-up period. The proportion of deaths was significantly higher among those who tested CrAg positive (25%
vs 9.4%; P = .01). Thirty-six percent (n = 9 of 25) of the overall
deaths occurred during the first 90 days. Forty-two percent
(n = 3) of the 7 overall deaths in the CrAg-positive group occurred during the first 90 days of follow up. Of 9 individuals
who tested positive in serum but negative in CSF, no deaths
were reported after a 12-month follow-up period. Furthermore,
none of these individuals developed CM during the same
follow-up period.
Among those individuals who received fluconazolebased therapy for CNS involvement, 57.1% (4 of 7) died
during their hospitalization. In contrast, among individuals who received combined therapy with fluconazole and
amphotericin B deoxycholate, 25.0% (3 of 12) died during
their hospitalization.
Individuals who tested positive for CrAg were at a higher
risk of death after adjusting for sex and use of ART at baseline (hazard ratio, 2.69; 95% confidence interval, 1.07–6.84)
(Figure 2). Three percent (n = 5) of the participants in the
CrAg-negative group were lost to follow up. Loss to follow up
was not reported in the CrAg-positive group.

CrAg-negative group had also a higher median amount of
time taking ART. Recent findings show that enhanced prophylaxis with fluconazole reduces the frequency of cryptococcosis
among PWH [26]. Although prophylaxis for cryptococcal disease is not recommended in contexts in which the prevalence
is low [27], this could potentially be reconsidered in the setting of a low-resource country where the prevalence of CrAg
is potentially high, which is consistent with our study that reports one of the highest CrAg prevalence estimates in Latin
American and even worldwide.
Overall, this study reinforces the need of implementing CrAg
screening in Central America to determine the real burden of
cryptococcal antigenemia among PWH. Honduras currently
does not require CrAg testing as screening when HIV is newly
diagnosed or among PWH with CD4 ≤100 cells/mm3 as recommended by the WHO [13]. Furthermore, implementing CrAg
screening has proven to be cost-effective in low-resource settings [2, 5, 6] and should therefore be an option in Honduras,
taking into account this study where the prevalence of CrAg
positivity appears to be high.
One of the major limitations associated to our mortality
analysis is not being able to determine the amount of time
individuals in the cohort were taking ART during the study
period or previously limited our analysis. Furthermore, when
assessing mortality, we were not able to determine the causes
of death among the cohort. The methodology of testing individuals either in serum or CSF depending on clinical
manifestations at presentation might have led to bias in the
prevalence of CrAg in serum but not the overall CrAg prevalence. Finally, we were not able to determine (1) the compliance to ART among participants, (2) the rate of abandoning
ART among those who had being taking ART for a longer
time, and (3) how the result on CrAg testing would be affected
by this situation.
CONCLUSIONS

In conclusion, our study findings suggest there is a high prevalence of cryptococcal antigenemia among PWH in Central
American, even when compared with studies in Africa where
the HIV burden is higher. Systematic screening for CrAg should
be considered in the region based on our results to address this
major public health concern.
Acknowledgments
We thank to Dr. Carlos Leitzelar, head of the microbiology department
where the cryptococcal antigen samples were processed. We also thank Dr.
Roberto Flores from URC-Centers for Disease Control and Prevention
(CDC) for assistance with the logistics of undertaking this screening project.
Financial support. Cryptococcal antigen testing kits were donated
by URC-CDC, through U.S. President’s Emergency Plan for AIDS Relief
(PEPFAR) funding.
Potential conflict of interests. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of
Potential Conflicts of Interest.
Cryptococcal Antigenemia in Honduras • ofid • 5

Downloaded from https://academic.oup.com/ofid/article/8/1/ofaa557/5981349 by Washington University in St. Louis user on 27 February 2021

could explain potential differences of cryptococcal antigenemia
prevalence with our study. Moreover, a Brazilian cohort also
showed a prevalence of CrAg in CSF of 8.9% [8], comparable to
our findings where prevalence in CSF was almost 8%. However,
unlike the Honduran cohort, this study included only inpatient
participants. Likewise, a recent Argentinian cohort of HIV participants with CD4 ≤100 cells/mm3 reported to have a prevalence of 8.1% [9], which is also lower than what is reported in
our study. Thus, our finding suggests that the burden of cryptococcal antigenemia in Central America might be the highest
or among the highest in Latin America and therefore urges
the need of CrAg testing among individuals with HIV with
CD4 ≤100 cells/mm3.
Latin America ranks third in HIV prevalence worldwide
below Africa and Southeast Asia [19]. Likewise, when assessing the prevalence of CM, Latin America also ranks third
[1]. However, models that state that the burden of CM is high
in African countries include several studies performed at this
region, where CrAg testing is more frequent than in Latin
America. Therefore, Latin America might have a lower reported burden compared with Africa due to lack of access to
tools to diagnose this disease or lack of public health programs
that require testing for this disease. This is why our estimates in
this study become notable because with a significantly smaller
number of HIV cases, prevalence of cryptococcal antigenemia
might be similar [15, 20, 21] or even higher [4, 17, 22–24]
than in some African countries with a higher burden of HIV.
Therefore, our findings suggest that actual models of cryptococcal infections worldwide might not be accurate when assessing the burden of this disease in Central America.
The proportion of fatalities in our study was 11.4% among
the whole cohort. A recent report undertaken at a Brazilian
HIV clinic showed that overall mortality was 27%. However,
the Brazilian cohort performed CrAg testing in participants
with CD4 <200 cell/mm3 [8]. Nevertheless, our estimates
show that CrAg-positive individuals had a higher risk of
mortality compared with those who tested negative. This
concurs with what has been reported recently, where the risk
of death is almost 3 times higher among those individuals
who tested positive for CrAg [16, 25]. Likewise, this study in
a South African cohort of PWH with CD4 ≤100 cells/mm3
reported an overall mortality among CrAg-positive participants of 25% after 12 months follow up [16], which was
the same as our estimate. Furthermore, our results reinforce
previous findings that mortality is still high among this particular set of patients even after implementing preemptive
therapy [16, 25].
Almost 50% of those individuals who tested negative for
CrAg were taking fluconazole for Candida infection prevention compared with only 25% among those who tested
positive. These differences could be explained by the fact
that individuals who were under fluconazole therapy in the
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